Related Experiment Video
Updated: Aug 2, 2026
08:45
Tissue Engineering of the Intestine in a Murine Model
Published on: December 1, 2012
Nortriptyline absorption in short bowel syndrome
J E Broyles1, R O Brown, T H Self
1Department of Clinical Pharmacy, University of Tennessee, Memphis.
Summary
Patients with severe short bowel syndrome can achieve therapeutic nortriptyline levels with oral medication. This finding is significant for oral drug therapy in patients requiring parenteral nutrition due to gastrointestinal issues.
Area of Science:
- Pharmacology
- Gastroenterology
- Clinical Medicine
Background:
- Severe short bowel syndrome (SBS) often necessitates parenteral nutrition (PN) due to impaired nutrient and drug absorption.
- Oral drug therapy efficacy can be compromised in SBS patients because of a shortened gastrointestinal tract.
Observation:
- A case study involving a patient with SBS requiring PN was conducted.
- The patient was administered nortriptyline orally.
Findings:
- The patient successfully achieved therapeutic nortriptyline serum concentrations via the oral route.
- This suggests oral drug administration is feasible in select SBS patients on PN.
Implications:
- This case highlights the potential for effective oral drug therapy in SBS patients, even when dependent on PN.
- Further research may explore optimizing oral drug absorption and achieving therapeutic levels in SBS populations.
- This finding could lead to improved medication management strategies for patients with significant gastrointestinal compromise.
Related Concept Videos
01:19Drug Absorption: Factors Affecting GI Absorption
The process of oral drug absorption can be influenced by several factors. Weakly acidic drugs tend to be absorbed more readily from the stomach due to their nonionized state. However, absorption may be less efficient in the upper intestine, where drugs are often ionized. Interestingly, despite the stomach's apparent advantage for drug absorption, its mucous layer can hinder diffusion. Its surface area is also smaller than the intestine's, which can further slow down the absorption rate.
In...
In...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:23Factors Influencing Drug Absorption: Anatomical Parameters
Drug absorption involves the movement of drugs from the point of administration into the systemic circulation. Initially, Gastrointestinal (GI) motility propels the drug through the digestive tract and into the stomach. However, the stomach's high acidity and limited surface area restrict its role in drug absorption for most drugs. The drug then moves from the stomach to the small intestine via gastric emptying, which can be slowed by various factors, including interactions with other...